A High Throughput Multiparametric Approach to Identifying Biologically Relevant Target Antibodies

There is a substantial interest in high quality, functional antibodies against membrane spanning proteins. Generating antibodies specific for these targets in their native conformation is very challenging, yet crucial for therapeutic and diagnostic antibody development.

The intrinsic advantage of in-solution, cell based assays over ELISA is that they facilitate the study of antibody-antigen interaction in their native environment: the cell surface. The iQue Screener scales up the throughput of such assays to several thousand samples/day, and it is a powerful tool to screen large antibody panels for properties beyond mere antigen binding.

This webinar will overview:

• How ModiQuest Research maximized their chances of finding therapeutic leads by implementing the iQue Screener platform.
• The use of the iQue Screener platform in various stages of antibody discovery campaigns, from stable target expressing cell line selection, to high throughput hybridoma screening, and finally to functional antibody lead characterization.
• The ability of the iQue Screener platform to simultaneously combine testing for control antigens, species cross reactivity and multiple antibody projects in a single primary screen.
• The key benefits of using no-wash, miniaturized, high throughput assay formats to screen large antibody libraries.

Speakers

Andrea Gorlani, Ph.D., Scientist, ModiQuest Research

Andrea Gorlani obtained his PhD from Utrecht University, where he studied the properties of HIV-neutralizing antibodies and their development as microbicidal drug. He continued his research on mechanisms of viral evasion and on antibody effector functions as a postdoc at Utrecht University and University of California, Irvine. In 2015, he joined ModiQuest Research where he is responsible for the cell culture division. Together with his team, he introduced the ModiVacc™ technology, a novel live-cell immunization method to generate high affinity antibodies against poorly immunogenic membrane spanning proteins.

Message Presenter

Thomas Duensing, Ph.D., Chief Technology Officer, IntelliCyt Corporation

Tom has more than 17 years of experience in scientific research, drug discovery and product development in the area of assay, applications and reagent systems. Tom was Senior Director of In Vitro Pharmacology at Tanox, where he built a successful assay development and high throughput screening program which contributed to the advancement of therapeutic monoclonal antibody candidates into clinical development. Prior to Tanox, Tom was Director of Assay Development at Cellomics and has also held research scientist positions at the National Institutes of Health’s Rocky Mountain Labs and Syntex.

Message Presenter